Analysts Offer Insights on Healthcare Companies: Centene (CNC), Haleon PLC (GB:HLN) and Ultragenyx Pharmaceutical (RARE)
Stephens Adjusts Price Target on Centene to $73 From $77
Centene Downgraded at Jefferies Amid Higher Medicaid Utilization
TD Cowen Maintains Buy on Centene, Lowers Price Target to $80
A Quick Look at Today's Ratings for Centene(CNC.US), With a Forecast Between $69 to $90
Truist Financial Remains a Buy on Centene (CNC)
Centene Price Target Cut to $69.00/Share From $83.00 by Jefferies
Jefferies Downgrades Centene to Hold, Lowers Price Target to $69
Centene's Hold Rating Affirmed Amid Medicaid Margin Pressures and Exchange Market Uncertainties
Buy Rating Affirmed for Centene Amid Positive Financial Performance and Solid Guidance
Centene Analyst Ratings
Wells Fargo Maintains Overweight on Centene, Lowers Price Target to $81
Centene Analyst Ratings
Elevance Extends Losses as BofA Cuts on Medicaid Headwinds
Centene Analyst Ratings
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Centene (CNC) and Radnet (RDNT)
Jefferies Adjusts Price Target on Centene to $83 From $90
The Latest Analyst Ratings For Centene
Centene Analyst Ratings
JPMorgan Adjusts Price Target on Centene to $80 From $85